2024-03-13 16:01 | UU:CHRS | | News Release200 | Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update |
2024-03-05 16:01 | UU:CHRS | | News Release200 | Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 |
2024-03-04 01:00 | UU:CHRS | | News Release200 | Coherus Completes Divestiture of Ophthalmology Franchise |
2024-02-23 17:33 | UU:CHRS | | News Release200 | Coherus BioSciences Announces New Employment Inducement Grants |
2024-02-21 08:30 | UU:CHRS | | News Release200 | Coherus Announces U.S. Launch of UDENYCA ONBODY ¢ „ ¢ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv |
2024-02-05 08:00 | UU:CHRS | | News Release200 | Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP |
2024-01-22 01:15 | UU:CHRS | | News Release200 | Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal |
2024-01-18 16:05 | UU:CHRS | | News Release200 | Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium |
2024-01-04 08:00 | UU:CHRS | | News Release200 | INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI ¢ „ ¢ (toripalimab-tpzi) |
2024-01-03 09:00 | UU:CHRS | | News Release200 | Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference |
2024-01-02 08:29 | UU:CHRS | | News Release200 | Coherus Announces U.S. Launch of LOQTORZI ¢ „ ¢ |
2023-12-26 16:01 | UU:CHRS | | News Release200 | Coherus Announces FDA Approval of UDENYCA ONBODY ¢ „ ¢, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv |
2023-12-22 17:00 | UU:CHRS | | News Release200 | Coherus BioSciences Announces New Employment Inducement Grants |
2023-12-11 08:30 | UU:CHRS | | News Release200 | Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI ¢ „ ¢ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx |
2023-12-07 17:56 | UU:CHRS | | News Release200 | Coherus BioSciences Announces CFO Transition Plans |
2023-12-06 04:00 | UU:CHRS | | News Release200 | Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress |
2023-11-28 11:16 | UU:CHRS | | News Release200 | Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI ¢ „ ¢ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical As |
2023-11-06 16:08 | UU:CHRS | | News Release200 | Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights |
2023-11-03 08:30 | UU:CHRS | | News Release200 | Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC) |
2023-11-02 20:00 | UU:CHRS | | News Release200 | Coherus BioSciences to Participate at Upcoming November Investor Conferences |
2023-10-30 18:00 | UU:CHRS | | News Release200 | Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023 |
2023-10-27 15:07 | UU:CHRS | | News Release200 | Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI ¢ „ ¢ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) |
2023-10-24 19:41 | UU:CHRS | | News Release200 | Coherus BioSciences Announces New Employment Inducement Grants |
2023-10-14 12:30 | UU:CHRS | | News Release200 | Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics |
2023-10-05 08:30 | UU:CHRS | | News Release200 | Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA ‚ ® ONBODY ¢ „ ¢ |
2023-10-04 08:30 | UU:CHRS | | News Release200 | CIMERLI ‚ ® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch |
2023-10-02 09:00 | UU:CHRS | | News Release200 | Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day |
2023-09-27 09:10 | UU:CHRS | | News Release200 | Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) |
2023-09-25 08:30 | UU:CHRS | | News Release200 | FDA Issues Complete Response Letter (CRL) for UDENYCA ‚ ® ONBODY ¢ „ ¢ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections |
2023-09-22 21:00 | UU:CHRS | | News Release200 | Coherus BioSciences Announces New Employment Inducement Grants |
2023-09-08 09:06 | UU:CHRS | | News Release200 | Coherus Completes Surface Oncology Acquisition |
2023-09-01 16:01 | UU:CHRS | | News Release200 | Coherus BioSciences to Participate at Upcoming ‚ September Investor Conferences |
2023-08-31 16:01 | UU:CHRS | | News Release200 | Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote ¢ € œFOR ¢ € the Proposed Merger with Coherus BioSciences |
2023-08-22 17:35 | UU:CHRS | | News Release200 | Coherus BioSciences Announces New Employment Inducement Grants |
2023-08-02 16:01 | UU:CHRS | | News Release200 | Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights |
2023-07-26 16:05 | UU:CHRS | | News Release200 | Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023 |
2023-07-21 17:30 | UU:CHRS | | News Release200 | Coherus BioSciences Announces New Employment Inducement Grants |
2023-07-20 16:05 | UU:CHRS | | News Release200 | Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors |
2023-07-13 08:30 | UU:CHRS | | News Release200 | Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY ¢ „ ¢ |
2023-07-03 08:30 | UU:CHRS | | News Release200 | Coherus Launches YUSIMRY ¢ „ ¢, a Biosimilar of Humira ‚ ®, at $995 per Carton in U.S. |
2023-06-26 21:08 | UU:CHRS | | News Release200 | Coherus BioSciences Announces New Employment Inducement Grants |
2023-06-16 07:01 | UU:CHRS | | News Release200 | Coherus to Acquire Surface Oncology |
2023-06-16 07:01 | UU:CHRS | | News Release200 | Coherus to Acquire Surface Oncology |
2023-06-05 17:30 | UU:CHRS | | News Release200 | Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma |
2023-06-01 08:33 | UU:CHRS | | News Release200 | Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY ¢ „ ¢, a HUMIRA ‚ ® biosimilar, available to patients |
2023-06-01 08:30 | UU:CHRS | | News Release200 | Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY ¢ „ ¢ (adalimumab-aqvh) Launching in July 2023 |
2023-05-22 08:30 | UU:CHRS | | News Release200 | Coherus Announces U.S. Launch of UDENYCA ‚ ® Autoinjector |
2023-05-16 06:50 | UU:CHRS | | News Release200 | Coherus Prices Public Offering of Common Stock |
2023-05-15 16:01 | UU:CHRS | | News Release200 | Coherus Announces Proposed Public Offering of Common Stock |
2023-05-08 16:05 | UU:CHRS | | News Release200 | Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights |
2023-05-04 16:30 | UU:CHRS | | News Release200 | Coherus BioSciences to Present at Upcoming Investor Conferences in May |
2023-05-01 16:07 | UU:CHRS | | News Release200 | Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023 |
2023-04-27 08:05 | UU:CHRS | | News Release200 | Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting |